Cellumen

Cellumen is the leading innovator in cellular systems biology (CSB™) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen’s CSB solutions are driving Discovery Toxicology by addressing the full complexity of disease and safety. Leading global organizations, such as the Mayo Clinic, Hamamatsu Photonics K.K, the EPA, FDA, NIH and top pharmaceutical companies, partner with Cellumen. Cellumen is a partner company of Safeguard Scientifics. Other investors include Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works. For more information about Cellumen, please visit